Matthias Scheffler

14PUBLICATIONS
190CO-AUTHORS
Molecular targetsPredictive and prognostic markersGene expression (incl. microarray and other genome-wide approaches)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Oct 08, 2026
FIND: a phase-II study to evaluate the efficacy and safety of erdafitinib in FGFR-altered NSCLC.

|Jun 10, 2026
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses.

|Dec 19, 2025
Molecular and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer Harboring KRAS G12V Mutations.

Felix John, Lea Ruge, Malte Verheyen

|Nov 11, 2024
Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-score.

Christoph Arolt, Andreas H Scheel, Margaret Dugan

|Oct 09, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do

|Apr 17, 2023
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.

Marcelo V Negrao, Haniel A Araujo, Giuseppe Lamberti

Pageof 3

Frequent Collaborators

6 joint publications

Reinhard Büttner

5 joint publications

Jürgen Wolf

4 joint publications

Sebastian Yves Friedrich Michels

4 joint publications

Rieke N Fischer